Disease prevention moves could save USA $16B pa within five years

27 July 2008

A small strategic investment in disease prevention could result in significant savings in US health care costs, according to a report from the Trust for America's Health, titled Prevention for a Healthier America: Investments in Disease Prevention Yield Significant Savings, Stronger Communities. In this, the TFAH finds that an investment of $10 per person a year in proven community-based programs to increase physical activity, improve nutrition and prevent smoking and other tobacco use could save the country more than $16.0 billion annually within five years. This is a return of $5.60 for every $1.

"Health care costs are crippling the US economy. Keeping Americans healthier is one of the most important, but overlooked ways we could reduce these costs," said Jeff Levi, executive director of the TFAH. "This study shows that, with a strategic investment in effective, evidence-based disease prevention programs, we could see tremendous returns in less than five years - sparing millions of people from serious diseases and saving billions of dollars," he added. Out of the $16.0 billion, Medicare could save more than $5.0 billion, Medicaid over $1.9 billion and private payers in excess of $9.0 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight